Amisulpride in delusional disorders. An observational study;Amisulpride en los trastornos de ideas delirantes. Estudio observacional

Archivos de Psiquiatria

Volumn 68, Issue 4, 2005, Pages 301-308

  Bertolín Guillén, José Manuel ^a   Piles De La Fuente, Pilar ^a   Vila Navarro, Cristina ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Adverse effects; Amisulpride; Delusional disorder; Effectiveness; Observational study; Tolerability

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR;

ADULT; AMENORRHEA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; DELUSIONAL DISORDER; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; FEMALE; GALACTORRHEA; HUMAN; MALE; MEMORY DISORDER; OBSERVATIONAL STUDY; PILOT STUDY; RETROSPECTIVE STUDY; SOMNOLENCE; STATISTICAL ANALYSIS;

EID: 32044439146     PISSN: 15760367     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl). 1996;124:154-8.
2. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14:209-18.
3. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y. Amisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27:1.071-81.
4. [Fe de erratas en: Neuropsychopharmacology 2003:28:611.]
5. Davis JM, Chen N, Click ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-64.
6. Moya Neto JIS, Lima MS, Soares BGO. Amisulpride for schizophrenia (Cochrane Review). En: The Cochrane Library, Issue 2. Oxford, UK: Update Software; 2003.
7. Leutch S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180-90.
8. Trabert W. 100 years of delusional parasitosis. Meta-analysis of 1.223 case reports. Psychopathology. 1995;28:238-46.
9. Silva H, Jerez S, Ramirez A, Renteria P, Aravena N, Salazar D, et al. Effects of pimozide on the psychopathology of delusional disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:331-40.
10. Sultana A, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev 2000;(3):CD001949.
11. Soares BGO, Fenton M, Chue P. Sulpiride for schizophrenia (Cochrane Review). En: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons; 2004.
12. WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Ginebra: WHO; 1993.
13. Racagni G, Canonico PL, Ravizza L, Pani L, Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology. 2004;50:134-43.
14. Linden M, Scheel T, Xaver Eich F. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol. 2004;19:111-9.
15. Candido CL, Romney DM. Depression in paranoid and nonparanoid schizophrenic patients compared with major depressive disorder. J Affect Disord. 2002;70:261-71.
16. Kohler CG, Lallart EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep. 2002;4:273-8.
17. Spitznagel MB, Suhr JA. Neuropsychological impairment associated with symptoms of schizotype: role of depressive and paranoid symptoms. J Nerv Ment Dis. 2004;192:382-4.
18. Baca Baldomero E, Roca Bennasar M, editores. Dopamina y esquizofrenia. Barcelona: Mayo; 2004.